Oxytetracycline in the treatment of ocular rosacea: a double-blind trial.
Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continuous treatment 19/35 patients achieved a sustained remission for 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.
D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D005128:Eye Diseases / Q000188:drug therapy*; D006801:Humans; D010118:Oxytetracycline / Q000627:therapeutic use*; D012393:Rosacea / Q000188:drug therapy*
D010118:Oxytetracycline